Enanta Pharmaceuticals’s Earnings: A Preview
Enanta Pharmaceuticals (NASDAQ:ENTA) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement.
Analysts estimate that Enanta Pharmaceuticals will likely report an Earnings Per Share (EPS) of $-1.22
JMP Securities Maintains Market Outperform on Enanta Pharmaceuticals, Lowers Price Target to $111
JMP Securities analyst Jason Butler maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Market Outperform and lowers the price target from $121 to $111.
Expert Ratings For Enanta Pharmaceuticals
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:
SVB Leerink Maintains Market Perform on Enanta Pharmaceuticals, Raises Price Target to $92
SVB Leerink analyst Roanna Ruiz maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Market Perform and raises the price target from $55 to $92.
JMP Securities Maintains Market Outperform on Enanta Pharmaceuticals, Raises Price Target to $77
JMP Securities analyst Jason Butler maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Market Outperform and raises the price target from $73 to $77.
Enanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has reported new preclinical data for EDP-235, its recently announced lead oral protease inhibitor for COVID-19. The…
Enanta Pharmaceuticals Highlights Presentation Of EDP-235 Data At World Health Organization (WHO) Virtual Conference 2021
- Demonstrated Highly Potent Antiviral Activity Against SARS-CoV-2 in Cellular Models -
- Once-Daily, Oral Dosing Supported by Optimized Pharmacokinetic Properties -
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)